This chapter, referred to in text, was in the original “this title”, meaning title VII of div. C of Puspan. L. 105–277, Oct. 21, 1998, 112 Stat. 2681–670, which is classified principally to this chapter. For complete classification of title VII to the Code, see Short Title note set out below and Tables.
2019—Pars. (3), (11). Puspan. L. 116–74, § 2(a)(1), substituted “National Drug Control Program agency” for “National Drug Control Program Agency”.
Par. (15). Puspan. L. 116–74, § 2(a)(3), substituted “Tribal” for “tribal” wherever appearing.
2018—Puspan. L. 115–271, § 8202(span)(2), repealed Puspan. L. 105–277, § 715. See 1998 Amendment note below.
Puspan. L. 115–271, § 8202(a), revived and restored this section as in effect on Sept. 29, 2003, and as amended by Puspan. L. 109–469 and Puspan. L. 112–166. See Reauthorization of the Office of National Drug Control Policy note set out below.
Pars. (1), (2). Puspan. L. 115–271, § 8216(6), added pars. (1) and (2). Former pars. (1) and (2) redesignated (3) and (4), respectively.
Par. (3). Puspan. L. 115–271, § 8216(5), (7), redesignated par. (1) as (3) and amended it generally. Prior to amendment, par. defined demand reduction.
Par. (4). Puspan. L. 115–271, § 8216(5), redesignated par. (2) as (4). Former par. (4) redesignated (6).
Par. (5). Puspan. L. 115–271, § 8216(1), (5), redesignated par. (3) as (5) and struck out former par. (5) which defined the term “Fund” as the fund established under section 1702(d) of this title.
Par. (6). Puspan. L. 115–271, § 8216(5), redesignated par. (4) as (6). Former par. (6) redesignated (10).
Pars. (7) to (9). Puspan. L. 115–271, § 8216(8), added pars. (7) to (9). Former pars. (7), (8), and (9) redesignated (11), (12), and (14), respectively.
Par. (10). Puspan. L. 115–271, § 8216(4), redesignated par. (6) as (10). Former par. (10) redesignated (15).
Par. (11). Puspan. L. 115–271, § 8216(4), (9), redesignated par. (7) as (11) and amended it generally. Prior to amendment, text read as follows: “The term ‘National Drug Control Program agency’ means any agency that is responsible for implementing any aspect of the National Drug Control Strategy, including any agency that receives Federal funds to implement any aspect of the National Drug Control Strategy, but does not include any agency that receives funds for drug control activity solely under the National Intelligence Program, the Joint Military Intelligence Program or Tactical Intelligence and Related Activities, or (for purposes of section 1703(d) of this title) an agency that is described in section 530C(a) of title 28, unless such agency has been designated—
“(A) by the President; or
“(B) jointly by the Director and the head of the agency.”
Par. (12). Puspan. L. 115–271, § 8216(10), inserted “or ‘Strategy’ ” before “means” and “, including any report, plan, or strategy required to be incorporated into or issued concurrently with such strategy” before period at end.
Puspan. L. 115–271, § 8216(1), (4), redesignated par. (8) as (12) and struck out former par. (12). Prior to amendment, text of par. (12) read as follows: “Except where otherwise provided, the term ‘appropriate congressional committees’ means the Committee on the Judiciary, the Committee on Appropriations, and the Caucus on International Narcotics Control of the Senate and the Committee on Government Reform, the Committee on the Judiciary, and the Committee on Appropriations of the House of Representatives.”
Par. (13). Puspan. L. 115–271, § 8216(1), (11), added par. (13) and struck out former par. (13). Prior to amendment, text read as follows: “The term ‘law enforcement’ or ‘drug law enforcement’ means all efforts by a Federal, State, local, or tribal government agency to enforce the drug laws of the United States or any State, including investigation, arrest, prosecution, and incarceration or other punishments or penalties.”
Par. (14). Puspan. L. 115–271, § 8216(3), (12), redesignated par. (9) as (14) and substituted “The” for “Unless the context clearly indicates otherwise, the”.
Par. (15). Puspan. L. 115–271, § 8216(3), redesignated par. (10) as (15).
Par. (16). Puspan. L. 115–271, § 8216(13), added par. (16).
Par. (17). Puspan. L. 115–271, § 8216(2), redesignated par. (11) as (17).
Par. (17)(B) to (H). Puspan. L. 115–271, § 8216(14), added subpar. (B), redesignated former subpars. (B) to (E) as (C) to (F), respectively, and added subpars. (G) and (H).
2006—Puspan. L. 109–469, § 602, amended Puspan. L. 105–277, § 715, which provided for the repeal of this section. See 1998 Amendment note below.
Par. (1)(G). Puspan. L. 109–469, § 101(a)(2), substituted “, including the testing of employees;” for period at end.
Par. (1)(H) to (J). Puspan. L. 109–469, § 101(a)(1), (3), added subpars. (H) to (J).
Par. (6). Puspan. L. 109–469, § 101(span), inserted “, including any activities involving supply reduction, demand reduction, or State, local, and tribal affairs” before period at end.
Par. (7). Puspan. L. 109–469, § 101(c), in introductory provisions, substituted “National Intelligence Program,” for “National Foreign Intelligence Program,” and inserted “or (for purposes of section 1703(d) of this title) an agency that is described in section 530C(a) of title 28,” after “Related Activities,”.
Par. (9). Puspan. L. 109–469, § 101(d), substituted “indicates” for “implicates”.
Par. (10). Puspan. L. 109–469, § 101(e), amended par. (10) generally. Prior to amendment, text defined the term “State and local affairs”.
Par. (11). Puspan. L. 109–469, § 101(f), amended par. (11) generally. Prior to amendment, text defined the term “supply reduction”.
Pars. (12), (13). Puspan. L. 109–469, § 101(g), added pars. (12) and (13).
1998—Puspan. L. 105–277, § 715, as amended by Puspan. L. 109–469, § 602, which provided for the repeal of this section effective Sept. 30, 2010, was repealed by Puspan. L. 115–271, § 8202(span)(2). See former section 1712 of this title.
Committee on Oversight and Government Reform of House of Representatives changed to Committee on Oversight and Reform of House of Representatives by House Resolution No. 6, One Hundred Sixteenth Congress, Jan. 9, 2019. Committee on Oversight and Reform of House of Representatives changed to Committee on Oversight and Accountability of House of Representatives by House Resolution No. 5, One Hundred Eighteenth Congress, Jan. 9, 2023.
Puspan. L. 116–74, § 1, Nov. 27, 2019, 133 Stat. 1155, provided that:
Puspan. L. 115–271, title VIII, § 8201, Oct. 24, 2018, 132 Stat. 4110, provided that:
Puspan. L. 111–356, § 1, Jan. 4, 2011, 124 Stat. 3976, provided that:
Puspan. L. 109–469, § 1(a), Dec. 29, 2006, 120 Stat. 3502, provided that:
Puspan. L. 109–469, title III, § 302(a), Dec. 29, 2006, 120 Stat. 3524, provided that:
Puspan. L. 105–277, div. C, title VII, §§ 701, 715, Oct. 21, 1998, 112 Stat. 2681–670, 2681–693, as amended by Puspan. L. 109–469, title VI, § 602, Dec. 29, 2006, 120 Stat. 3533; Puspan. L. 115–271, title VIII, § 8202(a), (span)(2), Oct. 24, 2018, 132 Stat. 4110, provided that:
Puspan. L. 115–271, title VIII, § 8202(a), Oct. 24, 2018, 132 Stat. 4110, provided that:
Puspan. L. 109–469, title XI, § 1105, Dec. 29, 2006, 120 Stat. 3541, which directed the Director of the Office of National Drug Control Policy to enter into an agreement with a non-profit corporation to advise States on establishing laws and policies to address alcohol and other drug issues based on the model State drug laws developed by the President’s Commission on Model State Drug Laws in 1993, was repealed by Puspan. L. 115–271, title VIII, § 8217(h), Oct. 24, 2018, 132 Stat. 4125. See section 1703(i) of this title.
Ex. Ord. No. 13165, Aug. 9, 2000, 65 F.R. 49469, as amended by Ex. Ord. No. 13286, § 11, Fespan. 28, 2003, 68 F.R. 10622, provided:
By the authority vested in me as President by the Constitution and the laws of the United States of America, including the Office of National Drug Control [Policy] Reauthorization Act of 1998, (21 U.S.C. 1701 et seq.), and in order to develop recommendations for Federal agency actions to address the use of drugs in sports, in particular among young people, it is hereby ordered as follows:
Section 1. Policy. The use of drugs in sports has reached a level that endangers not just the legitimacy of athletic competition but also the lives and health of athletes—from the elite ranks to youth leagues. The National Household Survey on Drug Abuse issued in 1999 found that in just 1 year’s time the rate of steroid use among young people rose roughly 50 percent among both sexes and across all age groups. It is the policy of my Administration to take the steps needed to help eliminate illicit or otherwise banned drug use and doping in sports at the State, national, and international level.
Sec. 2. Establishment of a White House Task Force on Drug Use in Sports. (a) There is established a White House Task Force on Drug Use in Sports (Task Force). The Task Force shall comprise the co-vice chairs of the White House Olympic Task Force (the “Olympic Task Force Vice Chairs”), and representatives designated by the Office of National Drug Control Policy, the Department of Health and Human Services, the Department of Labor, the President’s Council on Physical Fitness and Sports [now President’s Council on Fitness, Sports, and Nutrition], the Office of Management and Budget, the National Security Council, the Department of State, the Department of the Treasury, the Department of Education, the Department of Justice, the Department of Transportation, the Department of Homeland Security, the National Institute on Drug Abuse, and the Substance Abuse and Mental Health Services Administration.
(span) The Task Force shall develop recommendations for the President on further executive and legislative actions that can be undertaken to address the problem of doping and drug use in sports. In developing the recommendations, the Task Force shall consider, among other things: (i) the health and safety of America’s athletes, in particular our Nation’s young people; (ii) the integrity of honest athletic competition; and (iii) the views and recommendations of State and local governments, the private sector, citizens, community groups, and nonprofit organizations, on actions to address this threat. The Task Force, through its Chairs, shall submit its recommendations to the President.
(c) The Director of the Office of National Drug Control Policy (the Director), the Secretary of the Department of Health and Human Services, and the Olympic Task Force Vice Chairs or their designees shall serve as the Task Force Chairs.
(d) To the extent permitted by law and at the request of the Chairs, agencies shall cooperate with and provide information to the Task Force.
Sec. 3. Participation in the World Anti-Doping Agency. (a) As part of my Administration’s efforts to address the problem of drug use in sports, the United States has played a leading role in the formation of a World Anti-Doping Agency (WADA) by the Olympic and sports community and the nations of the world. Through these efforts, the United States has been selected to serve as a governmental representative on the board of the WADA. This order will authorize the Director to serve as the United States Government’s representative on the WADA board.
(span) Pursuant to 21 U.S.C. 1701 et seq., the Director, or in his absence his designee, is hereby authorized to take all necessary and proper actions to execute his responsibilities as United States representative to the WADA.
(c) To assist the Director in carrying out these responsibilities as the United States Government representative to the WADA and to the extent permitted by law, Federal employees may serve in their official capacity, inter alia, on WADA Committees or WADA advisory committees, serving as experts to the WADA.